All In Biotech

Drug Trial Radar · NCT06011200

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population

A Randomized, Blinded, Comparable Vaccine-controlled Phase IIIb Clinical Trial to Evaluate the Safety and Immunogenicity of Meningococcal Polysaccharide Conjugate Vaccine, Group ACYW135 (CRM197 Vector), in a 4 to 6 Year-old Population

Last checked: Nov 19, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,000

Actual

Start

Sep 16, 2023

Primary completion

Dec 11, 2023

Study completion May 11, 2024

Sponsor

Lead sponsor
CanSino Biologics Inc.Industry
Sponsor type
Industry
First posted
Aug 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 4 years, up to 6 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The scientific name of meningococcus is Neisseria meningitidis (Nm), the causative agent of epidemic meningococcal meningitis (rheumatoid encephalitis), which colonizes the mucous membranes of the human nasopharynx or causes local infection and can cross the mucosal barrier to cause invasive bacteremia or epidemic meningococcal meningitis, meningococcus can often cause serious disease epidemics worldwide, the main clinical features of its infection are fever, rash and meningitis, the most common clinical manifestation is acute bacterial meningitis.

Conditions

  • Epidemic Meningitis

Interventions

  • MCV4Biological

    1 dose of MCV4 on Day 0

  • MSPV4Biological

    1 dose of MSPV4 on Day 0

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric mean titers (GMT) of meningococcal antibodies to groups A, C, Y and W135 in all subjects 30 days after immunizationTime frame: 30 days after immunization
  2. Positive conversion rates of meningococcal antibodies to groups A, C, Y and W135 in all subjects 30 days after immunizationTime frame: 30 days after immunization
  3. Incidence of adverse reactions within 30 minutes after immunization in all subjectsTime frame: Within 30 minutes after immunization
  4. Incidence of adverse reactions/events within 7 days of immunization for all subjectsTime frame: Within 7 days after immunization
  5. Incidence of adverse reactions/events within 30 days of exemption for all subjectsTime frame: Within 30 days of exemption

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanyang County Center for Disease Prevention and Control

    Shanyang, Shaanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.